ProPhase Labs to Present at the Q4 Investor Summit Conference

Rhea-AI Summary

ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the virtual Q4 Investor Summit Conference on November 16, 2021, at 2:00 PM ET. The conference runs from November 16-17, 2021, and investors can register online. Karkus will also be available for one-on-one meetings during the event.

ProPhase Labs focuses on genomics testing, COVID-19 testing, and consumer healthcare products. The company aims to leverage its CLIA lab services for whole genome sequencing and has a broad range of diagnostic services.

GARDEN CITY, NY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Q4 Investor Summit Conference, which is being held virtually from November 16 – 17, 2021.

Mr. Karkus will deliver his corporate presentation on November 16 at 2:00 PM ET.

Investors can register here: https://investorsummitgroup.com/

Mr. Karkus will be available for one-on-one meetings throughout the conference.

About ProPhase Labs
ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research.

ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

ProPhase Diagnostics offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients who may have SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Critical to COVID testing, results are provided in under 24 hours. ProPhase Diagnostics also offers PCR (polymerase chain reaction) testing for Influenzas A and B and RSV; as well as antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Global Healthcare, Inc. was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements^® brand.

ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

Contact:

CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com

FAQ

When will ProPhase Labs present at the Investor Summit Conference?

ProPhase Labs will present on November 16, 2021, at 2:00 PM ET.

How can investors register for the Q4 Investor Summit Conference?

Investors can register for the conference by visiting the official Investor Summit website.

What is the focus of ProPhase Labs?

ProPhase Labs focuses on genomics testing, COVID-19 testing, and providing healthcare products and services.

Is Ted Karkus available for one-on-one meetings during the conference?

Yes, Ted Karkus will be available for one-on-one meetings throughout the conference.

What services does ProPhase Diagnostics provide?

ProPhase Diagnostics offers clinical diagnostic testing, including COVID-19 testing and PCR testing for other respiratory viruses.